Zydus Lifesciences Limited has informed the Exchange regarding a press release dated January 15, 2026, titled "Zydus receives final approval from USFDA for Eltrombopag Tablets,12.5 mg, 25 mg, 50 mg, and 75 mg".
Press Release Jan 15 2026
Filed with NSE · · 2 pages · English
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Zydus Lifesciences Limited completes the acquisition of Agenus Inc.'s biologics manufacturing facilities, launches Zylidac Bio LLC in the U.S.
- Press Release Jan 13 2026
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO(R), an Interchangeable Biosimilar to Lucentis(R)
- Press Release Dec 23 2025
- Zydus Partners with Bioeq for U.S. Commercialisation rights for NUFYMCO®, an Interchangeable Biosimilar to Lucentis®
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Jan 22 2026
- Press Release Jan 23 2026
- Press Release Feb 04 2026
- Press Release Feb 06 2026
- Press Release Feb 09 2026
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences